letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...2324252627282930313233...100101»
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Review, Journal:  Targeting the PI3K Pathway in Gynecologic Malignancies. (Pubmed Central) -  Nov 20, 2022   
    In gynecologic malignancies, alterations in PI3K signaling are common. Therefore, developing modulators of the PI3K pathway and identifying molecular markers to predict response are of great interest for these cancer types.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. (Pubmed Central) -  Nov 19, 2022   
    This fully oral, chemotherapy-free, triplet combined therapy has the potential to be an alternative neoadjuvant regimen for patients with TPBC. Our findings suggest the association between obesity/metabolic syndrome and breast cancer recurrence is better reflected by response to treatment than tumor-intrinsic properties, suggesting interventions to reverse obesity and/or MS may improve outcomes for breast cancer recurrence.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Acetate: A therapeutic candidate against renal disorder in a rat model of polycystic ovarian syndrome. (Pubmed Central) -  Nov 19, 2022   
    Eight-week-old female Wistar rats were randomly distributed into four groups (n = 6), which received vehicle, sodium acetate (200 mg/kg), letrozole (1 mg/kg) and letrozole plus sodium acetate, respectively...However, supplementation with acetate significantly attenuated these anomalies. Collectively, the present results suggest that acetate abolishes renal dysfunction in experimentally induced PCOS animals by attenuating androgen excess, apoptosis, oxidative stress and NF-κB/NLRP3 immunoreactivity.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Review, Journal:  Recent Advancements in In Vitro Fertilisation. (Pubmed Central) -  Nov 18, 2022   
    Some technical discoveries in reproductive medicine have had a significant impact on innovations and treatment choices in other fields of medicine as well. The objective of this succinct review article is to quickly summarise and explain the advancements made in this intriguing area of medicine over the past 40 years.
  • ||||||||||  letrozole / Generic mfg., methotrexate / Generic mfg., gefitinib / Generic mfg.
    Retrospective data, Review, Journal:  Future Perspectives of Ectopic Pregnancy Treatment-Review of Possible Pharmacological Methods. (Pubmed Central) -  Nov 16, 2022   
    Another promising substance in EP treatment is gefitinib, an inhibitor of EGFR tyrosine domain which, combined with MTX, seems to constitute a more effective alternative in the management of tubal ectopic pregnancies...Absolute ethanol injections proved successful and safe in caesarean scar pregnancies management. Thus far, little is known about the use of those substances in the treatment of ectopic pregnancies, but already conducted studies seem to be promising.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Androgen receptors immunoreactivity in the rat brain of males with same-sex preference. (Pubmed Central) -  Nov 15, 2022   
    Same-sex preference was produced in male rats by the prenatal administration of the aromatase inhibitor, letrozole (0.56 μg/kg/ml s.c. G10-22) that usually produces 1-2 animals per litter with same sex preference, while the others retain a female sex preference...Serum levels of testosterone did not differ between groups. Data are discussed based on the role of AR in the hippocampus.
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  Letrozole: Pharmacology, toxicity and potential therapeutic effects. (Pubmed Central) -  Nov 15, 2022   
    It also causes apoptosis, necrosis, and fibrosis, which all result in the demise of cancer cells. Its central and peripheral effects on follicle formation, estrogen production in the ovaries, and their clinical implications are explored in detail in this work.
  • ||||||||||  Soltamox (tamoxifen citrate) / Jazz
    Enrollment closed, Trial completion date:  The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov) -  Nov 14, 2022   
    P2,  N=30, Active, not recruiting, 
    Its central and peripheral effects on follicle formation, estrogen production in the ovaries, and their clinical implications are explored in detail in this work. Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Nov 2023
  • ||||||||||  letrozole / Generic mfg.
    Management of precocious puberty in girls with McCune–Albright syndrome (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1536;    
    At 6 months of treatment, on the other hand, the number of thyroid nodules increased from 5 to 3 months to 8 to 6 months of treatment, the thyroid balance remained normal. McCune-Albright is a rare cause of peripheral puberty, easy to diagnose due to the association of the triad of precocious puberty, bone fibrous dysplasia and café au lait spot, the treatment is generally disappointing, unlike our patient who presented an excellent response but the stature prognosis is always at stake and does not constitute an indication for treatment with growth hormone.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Long-term follow-up of aromatase-inhibitor use in 3 family members with aromatase excess syndrome (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_997;    
    When started early, treatment with aromatase inhibitors in children with AEXS was found to prevent the development of gynecomastia and improve final height. In adult life, treatment with aromatase inhibitors in a very low dose resulted in improved physical strength and libido.
  • ||||||||||  anastrozole / Generic mfg.
    Case Series: Anastrozole Monotherapy for Non-Classic Congenital Adrenal Hyperplasia (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_582;    
    Monotherapy with AI can be an effective alternative in slowing down bone maturation and improving height outcomes in children with NC-CAH and normal adrenal cortisol production. All three patients had appropriate pubertal progression, normal ovarian ultrasounds, and normal bone mineral density accrual.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Journal:  Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial. (Pubmed Central) -  Nov 8, 2022   
    Further studies are needed to determine whether EHR data can yield reliable conclusions on treatment effects in oncology. The potential of hepatotoxicity can be examined by assessing the elevation of inflammation markers such as Calprotectin, which is an indicator that should be strictly taken into consideration when administering aromatase inhibitors as treatment.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial suspension, Combination therapy, Metastases:  Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) -  Nov 4, 2022   
    P1,  N=44, Suspended, 
    The beneficial effects of curcumin on PCOS rats included the alteration of serum hormone levels and recovery of morphological ovarian lesions, in which, PTEN, a new target, may play a role in regulating the IRS1/PI3K/GLUT4 pathway. Active, not recruiting --> Suspended
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Journal:  INNOVATIONS IN SURGERY TO PERFORM AN OVARIAN DRILLING. (Pubmed Central) -  Nov 4, 2022   
    The surgeon can choose the one that he masters best and that will involve the least risk for the patient. It is recommended to use bipolar energy.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Nov 3, 2022   
    P2,  N=19, Active, not recruiting, 
    It is recommended to use bipolar energy. Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2022 --> May 2023